Research
Current Research Trials
Title |
Sponsor |
Controlled Trial of 3, 4 Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS) PI: Shumaila Sultan MD |
Jacobus Pharmaceuticals
IRB: 1402212067 |
A Phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease (Protocol EFC14028) PI: Cheryl Smith MD, PhD |
Sanofi-Genzyme
IRB: 1707650500 |
Neuroelectrical Stimulation in Guillian Barre Syndrome PI: Cheryl Smith MD, PhD |
Investigator-initiated
IRB: 1703497861 |
A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH): PI: Umer Najib MD |
Teva Branded Pharmaceutical Products R & D CRO: ICON
IRB: 1709763860
|
Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication Overuse The MOTS Trial: Medication Overuse Treatment Strategy PI: David B. Watson MD/Kristina Lopez MD |
Patient Centered Outcomes Research Institute (PCORI)
IRB: 1801958083 |
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, SHAM-CONTROLLED STUDY OF NON-INVASIVE VAGUS NERVE STIMULATION (nVNS) FOR THE PREVENTION OF MIGRAINES. (PREMIUM II) PI: Umer Najib MD |
electroCore
IRB: 1809270321 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Progressive Forms of Multiple Sclerosis [Protocol M14-397] PI: Ann Murray MD |
AbbVie
IRB: 1811366960 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis [Protocol M18-918] PI: Ann Murray MD |
AbbVie
IRB: 1811367264 |
Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy (Core-VNS) [Protocol No. LNN-801] PI: Zubeda Sheikh |
LivaNova USA
Central IRB: WIRB IRB: 1811357136 |